drugset / Trial / NCT02324309

BIOD-531 vs. Humalog Mix 75/25 vs. Humulin R U-500 Post-Meal Glucose Control in Patients With Severe Insulin Resistance

NCT02324309

Phase 1/2 Completed 12 enrolled Biodel
RandomizedCrossoverSingle-blindTreatment

Summary

The study is designed to compare meal time glucose control associated with BIOD-531, a rapidly absorbed concentrated insulin to that associated with Humalog Mix 75/25 and Humulin R U-500 in patients with diabetes and severe insulin resistance.

Timeline

Start
2014-05
Primary completion
2014-11
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject BIOD-531 Protein / enzyme biologic 0.8 iu/kg Subcutaneous
Subject BIOD-531 Protein / enzyme biologic 1.2 iu/kg Subcutaneous
Comparator Humalog Mix 75/25 Unknown 0.8 iu/kg Subcutaneous
Comparator Humalog Mix 75/25 Unknown 1.2 iu/kg Subcutaneous
Comparator insulin aspart Protein / enzyme biologic 0.8 iu/kg Subcutaneous
Comparator insulin aspart Protein / enzyme biologic 1.2 iu/kg Subcutaneous

Indications